EvoGenix lists at 20 per cent premium
Thursday, 11 August, 2005
Antibody therapeutic developer EvoGenix (ASX:EGX) listed today on the Australian Stock Exchange at AUD$0.30, 20 per cent above its issue price of AUD$0.25.
Evogenix identifies and develops antibody-based drugs and the company's technology works in three ways: it humanises to reduce immune rejection of the original mouse antibody, optimises the antibody protein to increase potency, and conjugates to increase cell-killing activity of antibodies.
At the time of writing, shares were trading at $0.27.
"We're pretty happy about it all and the price seems to be looking pretty good," said EvoGenix CEO Merilyn Sleigh. "It's sitting around $0.26 - $0.27 which is really very good at the moment, given that biotech in general isn't the hot topic."
The company's IPO raised AUD$9 million through the issue of 36 million shares and closed oversubscribed.
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
